ArticleJournal of health, population, and nutrition2026
The remnant cholesterol inflammatory index and risk of future cardiovascular disease in early CKM syndrome: findings from CHARLS.
Article in Journal of health, population, and nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nonlinear association between remnant cholesterol inflammation index and incident stroke among middle-aged and older adults with hypertension: a CHARLS cohort study.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRemnant cholesterol and systemic inflammation are two key, interrelated pathways in atherosclerosis. We examined whether the remnant cholesterol inflammatory index (RCII; remnant cholesterol × C-reactive protein/10) predicts incident cardiovascular disease (CVD) among adults in early cardiovascular-kidney-metabolic (CKM) stages.
methodsWe analyzed 5,961 China Health and Retirement Longitudinal Study participants aged ≥ 45 years (baseline 2015; follow-up through 2020) classified as CKM stages 0-3 and free of baseline CVD. Incident CVD (heart disease or stroke) was identified from self-reported physician diagnoses. We used multivariable Cox models with hierarchical adjustment, assessed dose-response patterns using restricted cubic splines, and conducted prespecified subgroup and exploratory mediation analyses.
resultsOver a median follow-up of 5.00 years (IQR, 5.00-5.09), 1,080 incident CVD occurred (18.1%). Each 1-unit increase in log-RCII was associated with higher CVD risk in the fully adjusted model (hazard ratio [HR] 1.070, 95% CI 1.016-1.127; P = 0.010). Compared with quartile 1, quartile 4 had increased risk (HR 1.239, 95% CI 1.029-1.492; P = 0.024; P for trend = 0.043). The dose-response association was linear (P for nonlinearity = 0.795), and no effect modification was detected (all P for interaction > 0.05). Systolic blood pressure mediated 5.0% (95% CI 1.10% to 17.00%) of the RCII-CVD association.
conclusionsHigher RCII was modestly associated with incident CVD across early CKM stages, suggesting a simple research marker to identify individuals at higher risk during a prevention window. Standardized thresholds and external validation of incremental predictive value are needed before clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.